港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

抗疫概念

876.550

+0.6340.07%

漲家數：7

跌家數：10

平家數：- -

市盈率：- -

高：885.329

開：878.139

低：871.523

收：875.916

成交量：1.05億

成交額：7.24億

市值：5,925.62億

流通市值：4,905.79億

資料載入中...

總覽新聞資訊

歌禮制藥納入港股通今日正式生效

歌禮制藥-B獲納入滬深港通下港股通名單

歌禮制藥-B(01672.HK)獲納入滬港通及深港通計劃項下的港股通名單

歌禮制藥－Ｂ(01672)股價下跌8.474%，現價港幣$9.235

阿斯达克财经

復星國際(00656.HK)：復星醫藥(02196.HK)減持印度注射劑藥品生產製造公司6%股權套現2.94億美元

阿斯达克财经

深交所：將歌禮制藥(01672)、曦智科技(01879)等調入深港通下的港股通標的

中國中藥(00570.HK)醒脾解鬱片獲批上市

阿斯达克财经

瑞銀：中國生物科技企業上半年銷售大多勝預期下半年全球研發催化劑成關鍵首選百濟神州(ONC.US)

港股異動 | 復星醫藥(02196.HK)早盤升逾5% 控股子公司279.96億印度盧比出售Gland Pharma約6.00%股權

禮邦醫藥-B公布H股獲納入港股通及恒生綜合指數

開拓藥業-B(09939.HK)：KT-939人體長期安全性試驗順利完成

2026年國家醫保談判在北京啓動；珍視明回應滴眼液抽檢不合格事件 | 醫藥早參

每日经济新闻

港股概念追蹤 | 創新藥賽道持續升温 AI提效向臨床縱深推進(附概念股)

復星醫藥(02196.HK)擬回購不超過10億港元H股

復星醫藥：擬12個月內回購不超過10億港元H股

南方财经网

復星醫藥(600196.SH)控股子公司擬出售Gland Pharma部分股權

迪哲醫藥高管發布減持計劃後，股價下跌超5%！公司回應：對長期發展充滿信心

每日经济新闻

銷量暴漲371%，中國車企卻在歐洲被經銷商追欠款半年

禮邦醫藥-B(09637)H股獲納入港股通及恒生綜合指數

中國中藥(00570)：1.1類中藥創新藥醒脾解鬱片獲批上市

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/BK1515/news?page=8"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1515","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","market":"HK","secType":"PLATE","nameCN":"抗疫概念","latestPrice":876.55,"timestamp":1789531191862,"preClose":875.9157,"halted":0,"volume":105391914,"delay":0,"changeRate":0.000724,"floatShares":0,"shares":0,"eps":0,"marketStatus":"交易中","change":0.634277,"latestTime":"09-16 11:59:52","open":878.13885,"high":885.32947,"low":871.5229,"amount":723639941,"amplitude":0.015762,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"午間休市","tradingStatus":4,"beginTime":1789531200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789522200000,1789531200000],[1789534800000,1789545600000]],"pbRate":1.316272,"peRate":17.057675,"turnoverRate":0.001444,"increases":7,"decrements":10,"flats":0,"marketCap":592561720832,"floatMarketCap":490579425216},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","high":885.32947,"amplitude":0.015762,"preClose":875.9157,"low":871.5229,"pbRate":"1.316272","latestPrice":876.55,"volume":105391914,"delay":0,"open":878.13885,"prevYearClose":1190.107,"prevWeekClose":878.789,"prevMonthClose":925.265,"prevQuarterClose":802.777,"fiveDayClose":912.778,"twentyDayClose":905.419,"sixtyDayClose":815.098,"secType":"PLATE","market":"HK","turnoverRate":0.001444,"peRate":17.057675,"marketCap":592561720832,"floatMarketCap":490579425216,"timestamp":1789531191862,"nameCN":"抗疫概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1515\",,,,undefined,":{"bkCode":"BK1515","up":7,"down":10,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1515\",pageSize:20,pageCount:8,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2665399941","title":"歌禮制藥納入港股通 今日正式生效","url":"https://stock-news.laohu8.com/highlight/detail?id=2665399941","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665399941?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 12:25","pubTimestamp":1788755100,"startTime":"0","endTime":"0","summary":"歌礼制药（01672）发布公告，公司于2026年9月7日起，获纳入沪港通及深港通计划下的港股通名单。此次纳入将使符合相关资格的国内投资者能够通过港股通渠道交易公司股票。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609073866532228.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609073866532228.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01477","BK1191","BK1515","FLHK","01672","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164090375","title":"歌禮制藥-B獲納入滬深港通下港股通名單","url":"https://stock-news.laohu8.com/highlight/detail?id=1164090375","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164090375?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 12:18","pubTimestamp":1788754680,"startTime":"0","endTime":"0","summary":"歌礼制药-B（Ascletis-B）宣布，公司已成功入选港股通名单，该名单适用于上海-香港股票市场交易互联互通机制以及深圳-香港股票市场交易互联互通机制。这一里程碑式的进展，标志着公司股票正式进入沪深港通体系，为两地投资者提供了更为便捷的投资通道。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","BK1515","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665352399","title":"歌禮制藥-B(01672.HK)獲納入滬港通及深港通計劃項下的港股通名單","url":"https://stock-news.laohu8.com/highlight/detail?id=2665352399","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665352399?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 12:16","pubTimestamp":1788754601,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","01672","BK1161","01477","BK1191","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665954633","title":"歌禮制藥－Ｂ(01672)股價下跌8.474%，現價港幣$9.235","url":"https://stock-news.laohu8.com/highlight/detail?id=2665954633","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665954633?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 10:35","pubTimestamp":1788748500,"startTime":"0","endTime":"0","summary":"[下跌股]歌礼制药－Ｂ(01672) 股价在上午10:35比前收市价下跌8.474%，现股价为港币$9.235。至目前为止，今日最高价为$10.57，而最低价为$9.235。总成交量为287.599万股，总成交金额为港币$2.858千万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180725131622959_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180725131622959_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2609071531/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2609071531/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["01672","BK1161","BK1515","BK1574","BK1191","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665839583","title":"復星國際(00656.HK)：復星醫藥(02196.HK)減持印度注射劑藥品生產製造公司6%股權  套現2.94億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2665839583","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665839583?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 10:03","pubTimestamp":1788746580,"startTime":"0","endTime":"0","summary":"复星国际公布，附属复星医药全资附属复星医药新加坡公司，通过大宗交易及集中竞价方式出售共计989.7万股Gland Pharma Limited股份，约占该公司股份总数的6%，出售事项的总代价约为279.96亿卢比。Gland Pharma Limited是一间根据印度法律成立的公司，其主要从事注射剂药品的生产制造业务，其股份于孟买证券交易所及印度国家证券交易所上市，股份代号：GLAND。于出售事项前及完成后，复星国际分别持有Gland Pharma约51.76%及45.76%的股权，该公司仍为复星医药及复星国际的附属。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220902164047308_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220902164047308_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1543112/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1543112/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1191","BK1230","02196","BK0188","BK1515","BK0060","MNDmain","BK0183","00656","600196","BK0096","BK0175","BK0196","BK0187","BK1593","BK0239","BK0028","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665930583","title":"深交所：將歌禮制藥(01672)、曦智科技(01879)等調入深港通下的港股通標的","url":"https://stock-news.laohu8.com/highlight/detail?id=2665930583","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665930583?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 09:57","pubTimestamp":1788746223,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，9月7日，深交所公告，根据《深圳证券交易所深港通业务实施办法》的有关规定，港股通标的证券名单发生调整并自2026年09月07日起生效。调入歌礼制药(01672)、曦智科技(01879)、百度集团(09888)等，调出日清食品(01475)、海昌海洋公园(02255)、狮腾控股(02562)等。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260907/32361455.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1163","01672","01879","BK1191","FLHK","BK1161","BK1574","01477","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665937733","title":"中國中藥(00570.HK)醒脾解鬱片獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2665937733","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665937733?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 09:57","pubTimestamp":1788746220,"startTime":"0","endTime":"0","summary":"中国中药(00570.HK) 公布，经国家药监局完成技术审评、现场核查、抽样检验等一系列工作程序，同济堂制药申报的1.1类中药创新药醒脾解郁片已获得批准上市，药品上市许可持有人为同济堂制药。(ha/a)(港股报价延迟最少十五分钟。沽空资料截至 2026-09-04 16:25。)AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20240130110317502_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20240130110317502_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1543108/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1543108/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1515","00570","BK1191","BK1606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665931133","title":"瑞銀：中國生物科技企業上半年銷售大多勝預期 下半年全球研發催化劑成關鍵 首選百濟神州(ONC.US)","url":"https://stock-news.laohu8.com/highlight/detail?id=2665931133","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665931133?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 09:41","pubTimestamp":1788745283,"startTime":"0","endTime":"0","summary":"瑞银指出，上述11家公司今年上半年产品销售总额同比增长34%。百济神州上调指引，信达生物提供新的乐观指引，其余公司均维持全年指引，有信心达成或超额完成。报告提到，中国生物科技对外授权交易仍然活跃，截至8月底，今年以来首付款及总交易规模已分别达到2025年全年水平的90%及82%。瑞银预计，今年下半年学术会议季将于9月展开，重点关注WCLC/ESMO实体肿瘤会议及ASH血液学会议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492581.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0307460666.USD","09926","01801","HK0000165453.HKD","LU2778985437.USD","LU0417516902.SGD","LU0348735423.USD","LU1961090484.USD","BK1588","LU0463099449.HKD","06160","688235","LU0417516738.SGD","LU1770034418.SGD","LU0348784397.USD","LU0348767384.USD","00013","BK1515","LU2097828474.EUR","03069","LU2476274308.USD","LU1969619763.USD","ONC","LU2328871848.SGD","LU2476274720.SGD","LU2097828557.USD","LU0244354667.USD","LU0561508036.HKD","LU2399975544.HKD","BK1583","LU0634319403.HKD","IE00B5MMRT66.SGD","BK0239","LU2097828631.EUR","01877","BK1161","LU0348783233.USD","LU1719994722.HKD","BK4139","LU2242644610.SGD","BK4588","LU1720050803.USD","LU1188198961.HKD","LU1303224171.USD","LU0348825331.USD","LU0455707207.USD","IE00B543WZ88.USD","09969","06990","KURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665935403","title":"港股異動 | 復星醫藥(02196.HK)早盤升逾5% 控股子公司279.96億印度盧比出售Gland Pharma約6.00%股權","url":"https://stock-news.laohu8.com/highlight/detail?id=2665935403","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665935403?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 09:35","pubTimestamp":1788744909,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02196","BK1191","BK1593","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665398982","title":"禮邦醫藥-B公布H股獲納入港股通及恒生綜合指數","url":"https://stock-news.laohu8.com/highlight/detail?id=2665398982","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665398982?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 08:50","pubTimestamp":1788742200,"startTime":"0","endTime":"0","summary":"模拟交易客户端礼邦医药-B公布，据港股通的相关安排及调整，公司H股获纳入港股通合资格证券名单，将自2026年9月7日（星期一）起生效。H股获纳入港股通乃基于其获纳入恒生综合指数。董事会认为，H股获纳入港股通及恒生综合指数，反映了资本市场对公司价值及长期发展前景的认可，并将有助于进一步扩大公司的投资者基础，提升H股的交易流动性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-09-07/doc-iniqyeua9585261.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1191","BK1515","BK1161","09637","HSCI","159938","09939","FLHK","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665601053","title":"開拓藥業-B(09939.HK)：KT-939人體長期安全性試驗順利完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2665601053","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665601053?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 08:01","pubTimestamp":1788739288,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09939","BK1161","BK1574","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665367071","title":"2026年國家醫保談判在北京啓動；珍視明回應滴眼液抽檢不合格事件 | 醫藥早參","url":"https://stock-news.laohu8.com/highlight/detail?id=2665367071","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665367071?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 07:01","pubTimestamp":1788735712,"startTime":"0","endTime":"0","summary":"丨2026年9月7日星期一丨NO.12026年国家医保谈判在北京启动9月5日，2026年国家医保目录谈判竞价和商保创新药目录价格协商在北京启动，预计持续4至5天。新版目录有望于11月底前公布，2027年1月1日起执行。与往年相比，今年国谈整体提前约一个月，已有59个创新药完成参考药预沟通，并新增创新药“预申报”。点评：预沟通与预申报缩短创新药准入周期，有利于药企加快商业化节奏。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609073866183218.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609073866183218.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["PBPH","BMED","BK1574","XLVI","09939","APXH","159938","BK1515","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665836774","title":"港股概念追蹤 | 創新藥賽道持續升温 AI提效向臨床縱深推進(附概念股)","url":"https://stock-news.laohu8.com/highlight/detail?id=2665836774","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665836774?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 06:53","pubTimestamp":1788735233,"startTime":"0","endTime":"0","summary":"西湖大学生命科学学院教授黄晶表示，AI辅助新药研发已不止于概念，而真正可以支撑原创药物从发现走向临床，直至上市。艾普司韦是西湖大学首款完全自主研发的1类创新药，用于成人轻型、中型新型冠状病毒感染的治疗。中国AI制药市场规模2025年已突破6亿元。从经营数据来看，AI相关业务正成为部分企业订单和收入增长的重要驱动力；与此同时，下游药企也在积极拥抱AI，研发提效成果逐步显现。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492510.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","VTHR","VXUS","BK1161","BK1574","02196","IBBQ","03696","BK1617","BK1141","LNGR","BK1593","02228","MEDX","KCAI","159992","AIPO","BK1191","ARTY","AGIX","BK4585","BK1515","QTOC","CHAT","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665517364","title":"復星醫藥(02196.HK)擬回購不超過10億港元H股","url":"https://stock-news.laohu8.com/highlight/detail?id=2665517364","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665517364?lang=zh_tw&edition=fundamental","pubTime":"2026-09-06 18:25","pubTimestamp":1788690331,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1593","BK1515","BK1191","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665364975","title":"復星醫藥：擬12個月內回購不超過10億港元H股","url":"https://stock-news.laohu8.com/highlight/detail?id=2665364975","media":"南方财经网","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665364975?lang=zh_tw&edition=fundamental","pubTime":"2026-09-06 18:12","pubTimestamp":1788689520,"startTime":"0","endTime":"0","summary":"南财智讯9月6日电，复星医药（02196.HK）发布自愿公告，基于对集团发展前景的信心及内在价值的认可，经董事会批准，公司拟自2026年8月27日起12个月内回购H股，回购资金总额不超过10亿港元。本次回购依据2026年6月16日股东周年大会、H股类别股东会及A股类别股东会授予董事会的H股回购一般性授权实施。回购H股用途包括注销或作为库存股份持有。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609063866106963.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609063866106963.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK0096","02196","BK0028","BK0060","BK0188","BK0183","BK0196","BK0012","BK1191","BK0187","600196","BK1593","BK0175","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665361715","title":"復星醫藥(600196.SH)控股子公司擬出售Gland Pharma部分股權","url":"https://stock-news.laohu8.com/highlight/detail?id=2665361715","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665361715?lang=zh_tw&edition=fundamental","pubTime":"2026-09-06 17:00","pubTimestamp":1788685207,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，印度时间2026年9月4日，公司控股子公司复星医药新加坡公司通过大宗交易及集中竞价方式出售共计989.70万股 Gland Pharma 股份，交易总对价为279.96亿印度卢比，均价约为2,828.78印度卢比/股、较前一交易日收盘价格折让约2.72%。紧随本次交易完成后，集团仍持有 Gland Pharma 约45.76%的股权、为其控股股东，Gland Pharma 仍为集团合并报表范围内子公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492481.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0175","BK0187","BK1191","BK0188","600196","BK1593","BK0028","02196","BK0060","BK0012","BK0183","BK0096","BK0196","BK1515","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665361549","title":"迪哲醫藥高管發布減持計劃後，股價下跌超5%！公司回應：對長期發展充滿信心","url":"https://stock-news.laohu8.com/highlight/detail?id=2665361549","media":"每日经济新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665361549?lang=zh_tw&edition=fundamental","pubTime":"2026-09-06 14:57","pubTimestamp":1788677820,"startTime":"0","endTime":"0","summary":"迪哲医药对每经记者表示，公司始终认为，上市公司股价的长期走势根本上取决于基本面和经营实绩，并对长期发展充满信心。2026年8月至今，迪哲医药自愿披露多份利好公告。2026年9月3日盘后，迪哲医药发布了关于董事、高级管理人员减持股份计划公告。在发布高管减持计划后的首个交易日，迪哲医药股价表现不佳，盘中跌幅一度超过6%，收盘下跌5.01%。截至9月4日，迪哲医药收盘价报57.01元，市值约为265.5亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-09-06/doc-iniqwnma6518378.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-09-06/doc-iniqwnma6518378.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159938","BK1515","BK1161","09939","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665361021","title":"銷量暴漲371%，中國車企卻在歐洲被經銷商追欠款半年","url":"https://stock-news.laohu8.com/highlight/detail?id=2665361021","media":"虎嗅APP","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665361021?lang=zh_tw&edition=fundamental","pubTime":"2026-09-06 11:06","pubTimestamp":1788663960,"startTime":"0","endTime":"0","summary":"相关报道称，多位德国经销商向媒体控诉，小鹏和比亚迪的付款周期长达半年以上，单店欠款普遍达到六位数欧元。对此，小鹏汽车方面公开表态确认存在延迟，但否认有任何故意拖延的意图。有经销商直言，中国车企对经销商“并非完全信任”，以至于层层设防，部分审批还要上报中国总部。其次，欧洲汽车经销合同有明确的行业惯例。一旦中国车企的付款行为被认定为“不公平商业行为”，车企可能面临法律诉讼和行业制裁。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MTQzMjE1NjQwMQ==&mid=2656200882&idx=2&sn=0187d8ceb8697f8fd5423a7ce15f69c7&chksm=67d904921b128560a56d737aec95ac17fc9a35669e8947fc481442c669e730fa119f2dcca557&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK0188","00285","LU1328277881.USD","LU0359201885.HKD","LU0214875030.USD","FDRV","SG9999015945.SGD","LU1868838027.USD","LU1242518857.USD","LU1242518931.SGD","002594","01211","BK1589","SG9999015952.SGD","XPEG","LU1303224171.USD","LU1023057109.AUD","LU0823426480.USD","LU0029874905.USD","LU0593848301.USD","LU0348735423.USD","LU0463099449.HKD","LU0327786744.USD","LU1770034418.SGD","SMOG","81211","LU1880383440.USD","BK1539","BK1515","BK1149","HYDD.SI","LU0269904917.USD","LU0348805143.USD","BYDDY","LU2778985437.USD","09868","LU0572944931.SGD","LU0605514214.HKD","LU2449936058.SGD","BK0169","XPEV","LU1961090484.USD","IE00BZ08YS42.EUR","EVS.SI","LU0823038988.USD","LU1580142542.USD","LU0509642566.USD","LU0143863784.USD","LU1997245177.USD","LU0289960550.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664332059","title":"禮邦醫藥-B(09637)H股獲納入港股通及恒生綜合指數","url":"https://stock-news.laohu8.com/highlight/detail?id=2664332059","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664332059?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 21:34","pubTimestamp":1788528840,"startTime":"0","endTime":"0","summary":"H股获纳入港股通乃基于其获纳入恒生综合指数。根据恒生指数有限公司于2026 年8月21日公布的截至2026年6月30日的恒生指数系列季度检讨结果，H股获纳入恒生综合指数成份股，有关变动已于2026年9月4日(星期五)收市后实施，并将自 2026年9月7日(星期一)起生效。董事会认为，H股获纳入港股通及恒生综合指数，反映了资本市场对公司价值及长期发展前景的认可，并将有助于进一步扩大公司的投资者基础，提升H股的交易流动性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492382.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","159938","09637","FLHK","BK1161","09939","BK1191","BK1574","HSCI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664334496","title":"中國中藥(00570)：1.1類中藥創新藥醒脾解鬱片獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2664334496","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664334496?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 20:50","pubTimestamp":1788526251,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国中药(00570)发布公告，有关国家药监局受理集团的附属公司国药集团同济堂（贵州）制药有限公司（同济堂制药）的1.1类中药创新药郁枢达片注册上市申请。经国家药监局完成技术审评、现场核查、抽样检验等一系列工作程序，同济堂制药申报的1.1类中药创新药醒脾解郁片（即先前公告所称“郁枢达片”，为该药品获国家药监局核准的规范通用名称）已获得批准上市，药品上市许可持有人为同济堂制药。醒脾解郁片具有醒脾化湿、理气解郁的功效，用于轻、中度抑郁症，症状为情绪郁闷、低落，表情淡漠、倦怠乏力、失眠多梦、少气懒言、食少纳呆，头重肢困、 口中黏腻、面色晦暗，舌淡苔白腻或灰腻、脉滑或弦。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492351.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00570","IPOS","06978","159992","BK1574","BK1515","IBBQ","BK1606","BK1161","MEDX","BK1191","LNGR"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":11,"pageCount":8,"totalSize":204,"code":"91000000","status":"200"}]}}